September 10 (UPI) – A foreign organization of scientists, in an open letter, last month announced Russian studies on COVID-19 vaccine studies through the Kremlin.
For example, the nine volunteers exposed to a vaccine formulation, they said, gave the impression of having the same antibody tites at 21 and 28 days, the same observed in seven of the nine volunteers who won some other formulation.
“Based on probabilistic assessments, it is highly unlikely to observe so many knowledge topics preserved among other experiments,” the letter says.
“Among the [other] teams of nine patients, who prove absolutely other things, you see exactly the same numbers,” Bucci told the Moscow Times. “It is very important to see so many duplications.
Russian studies published last week in the medical journal The Lancet for peer review, a key step in the approval procedure for any vaccine.
In their letter, scientists also expressed fear of the lack of original knowledge presented through Russian researchers in their article on The Lancet. Scientists at the Gamaleya National Centre for Epidemiology and Microbiology in Moscow reported that the vaccine was effective in generating antibodies in more than 70 healthy adults participating in a couple of early-stage trials.
“While the studies described in this review are potentially important, the presentation of knowledge raises several considerations that require original knowledge for further research.
Kirill Dmitriev, executive director of the Russian Direct Investment Fund, which has helped fund the progression of the vaccine, said the published effects were “the definitive answer to the series of questions directed against Russia. “
Moscow announced last month that the Sputnik V vaccine had been the first COVID-19 in the world registered for use, and Russian President Vladimir Putin said he had even given it to one of his daughters.
However, the vaccine was criticized by top fitness experts because no knowledge had been published and no last-stage tests had been performed. The knowledge published in The Lancet last week was the first to be had on the vaccine, and its appearance in the journal is a key step in the mandatory peer review procedure for any prospective medical advances.